EIF4E-IN-1

• Description:

  EIF4E-IN-1 is a potent inhibitor of eIF4E. eIF4E-IN-1 inhibits immunosuppression components such as immune checkpoint proteins PD-1, PD-L1, LAG3, TIM3, and/or IDO, in order to inhibit or release immune suppression in certain diseases, such as cancer and infectious disease (extracted from patent WO2021003194A1, compound Y) [1].

• UNSPSC:

  12352005

• Hazard Statement:

  H302-H315-H319-H335

• Target:

  Eukaryotic Initiation Factor (eIF)

• Type:

  Reference compound

• Related Pathways:

  Cell Cycle/DNA Damage

• Applications:

  COVID-19-anti-virus

• Field of Research:

  Cancer; Infection

• Assay Protocol:

  https://www.medchemexpress.com/eif4e-in-1.html

• Solubility:

  10 mM in DMSO

• Smiles:

  N#CC1=C(N2CCN(CC2)C)C(C(F)(F)F)=CC3=C1C(N(CCOC4=CC=C(C=C4C5=C(SC=C6C(O)=O)C6=NC(C)=C5)Cl)C(C)=N3)=O

• Molecular Formula:

  C33H28ClF3N6O4S

• Molecular Weight:

  697.13

• Precautions:

  P261-P264-P270-P271-P280-P302+P352-P304+P340-P305+P351+P338-P330-P362-P403+P233-P405-P501

• References & Citations:

  [1]Kevin R, et al. Eif4e inhibitors for use as immune checkpoint modulators and related methods. Patent WO2021003194A1.

• Shipping Conditions:

  Room temperature

• Scientific Category:

  Reference compound1

• Clinical Information:

  No Development Reported

• Isoform:

  EIF4

• CAS Number:

  [2573979-31-2]